BofA raises Guardant Health’s price target to $120 from $100, maintaining a Buy rating. Analysts expect headwinds to fade and markets to normalize in 2026. The firm sees potential in Biopharma spending, favoring companies with high research and development exposure.

Source: TheFly

For more information on Guardant Health, visit TipRanks’ Insider Trading Stocks section.

Find out more about GH: Disclaimer & Disclosure, Report an Issue.

Read more at Yahoo Finance: Guardant Health price target raised to $120 from $100 at BofA